• “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>Gen-Probe策略投资Pacific Biosciences 5千万美元

    靠赌博每天稳赚300元: Gen-Probe策略投资Pacific Biosciences 5千万美元

    Gen-Probe2012年7月17日 9:04 点击:2446

    时时彩网络平台 www.qlgr.net


       美国Pacific Biosciences


    Gen-Probe宣布对Pacific BioSCiencES策略投资5000万美元。

    Gen-Probe Makes $50 Million Strategic Investment in Third Generation Sequencing Company Pacific Biosciences

     

    Companies to Collaborate on Developing Products for Clinical Diagnostics Use --

     

    SAN DIEGO and MENLO PARK, Calif., June 17, 2010 /PRNewswire via COMTEX/ --Gen-Probe Incorporated (Nasdaq: GPRO) and Pacific Biosciences announced today that Gen-Probe has made a $50 million strategic investment in Pacific Biosciences, a private sequencing company. In addition, the companies will work together to explore co-development of new integrated clinical diagnostics systems based on Pacific Biosciences' Single Molecule Real Time (SMRT(TM)) platform and Gen-Probe's expertise in diagnostics.

    Gen-Probe and Pacific Biosciences will initially collaborate on an exclusive basis for up to 30 months, with the goal of developing a longer-term, preferred business relationship aimed toward improving the diagnosis of human diseases. The companies can also purchase certain of each others' products on preferential terms.

    "We believe Pacific Biosciences' third-generation, single-molecule sequencing technology has the potential to play an important long-term role in strategically valuable, high-growth clinical diagnostics markets such as oncology, transplant diagnostics and pharmacogenomics due to its fast time to result, long read lengths, and ability to interrogate broad genomic regions in high resolution," said Carl Hull, Gen-Probe's president and chief executive officer. "We are excited to collaborate with Pacific Biosciences to develop an innovative sequencing system based on their best-in-class technologies."

    Pacific Biosciences' SMRT DNA sequencing is expected to be a transformative technology that enables a new paradigm in genomic analysis. It enables, for the first time, the observation of natural DNA synthesis by a DNA polymerase as it occurs. The approach is based on eavesdropping on a single DNA polymerase molecule working in a continuous, processive manner.

    "We see a significant opportunity for our SMRT platform in the molecular diagnostics market and are taking a proactive and strategic approach by collaborating with Gen-Probe, a proven leader in developing fully automated instrument systems for nucleic acid testing," said Hugh Martin, chairman and chief executive officer of Pacific Biosciences. "We believe Gen-Probe's expertise in instrument systems engineering and sample preparation, combined with their capabilities in clinical and regulatory affairs, will help us maximize the potential of our sequencing technology to benefit human health."

    Gen-Probe's $50 million investment is part of a larger Series F private round of financing by Pacific Biosciences.

    About Pacific Biosciences

    Pacific Biosciences' mission is to transform the way humankind acquires, processes and interprets data from living systems. The company has developed a disruptive technology platform for the real-time detection of biological events at single molecule resolution. Single Molecule Real Time (SMRT) Biology is designed to revolutionize life sciences by revealing the underlying networks that define living systems. The first application for the SMRT Biology platform is a paradigm changing approach to DNA sequencing. The SMRT Sequencing System should ultimately make it possible to sequence individual genomes as part of routine medical care. DNA sequencing is expected to be the first of many transformative SMRT Biology applications that will benefit society by driving radical advances in fields such as personalized medicine, agriculture, clean energy, and global health.

    About Gen-Probe

    Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. Gen-Probe has approximately 27 years of expertise in nucleic acid testing, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,300 people. For more information, go to //www.genie.com/.

    As of March 31, 2010, Gen-Probe had $534.3 million of cash, cash equivalents and marketable securities, and $240.8 million of short-term debt. The Company generates roughly $10 million in free cash flow a month.

    Caution Regarding Forward-Looking Statements

    Any statements in this news release about Gen-Probe's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning future development efforts, possible or expected results of operations, regulatory approvals, future milestones, growth opportunities, and plans of management are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks, uncertainties and assumptions include but are not limited to: (i) the risk that our effort to develop sequencing systems with Pacific Biosciences will not be successful, (ii) the risk that any sequencing products we develop may not be approved by regulatory authorities or receive adequate reimbursement by payors, (iii) the possibility that the market for the sale of our sequencing products may not develop as expected, (iv) the risk that we will write down the value of our investment in Pacific Biosciences, (v) the risk that our ownership stake in Pacific Biosciences will be diluted by future financings, (vi) the risk that we may not be able to compete effectively, (vii) the risk that we may not be able to maintain our collaboration with Pacific Biosciences or enter into a further collaboration with them, (viii) the risk that our or Pacific Biosciences' intellectual property may be infringed by third parties or invalidated, and (ix) our involvement in patent and other intellectual property and commercial litigation could be expensive and could divert management's attention. This list includes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

    Contacts:
    Gen-Probe
    Michael Watts
    858-410-8673
    [email protected]

    Pacific Biosciences
    Nicole Litchfield
    415-793-6468
    [email protected]

    SOURCE Gen-Probe Incorporated

    (来源: Gen-Probe )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 山西十一选五遗漏号 开奖日出波规律 黑龙江22选5一等奖奖金多少 国外足彩投注网站 nba总决赛时间2019 陕西快乐十分直播 六合彩落球直击网站 怎么才能合买彩票 平码三中三公式十规律 年海南环岛赛 大乐透胆拖中奖计算器 江苏体彩11选五走势图 半波单双中特 辽宁快乐12投注秘诀 福建11选5开奖5结果